Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Revenue (2018 - 2025)

Serina Therapeutics' Revenue history spans 8 years, with the latest figure at $130000.0 for Q2 2025.

  • For Q2 2025, Revenue rose 154.9% year-over-year to $130000.0; the TTM value through Sep 2025 reached $116000.0, down 96.33%, while the annual FY2024 figure was $56000.0, 98.22% down from the prior year.
  • Revenue for Q2 2025 was $130000.0 at Serina Therapeutics, up from -$14000.0 in the prior quarter.
  • Across five years, Revenue topped out at $3.1 million in Q4 2023 and bottomed at -$14000.0 in Q4 2024.
  • The 5-year median for Revenue is $24000.0 (2021), against an average of $206882.4.
  • The largest annual shift saw Revenue surged 38487.5% in 2023 before it crashed 100.45% in 2024.
  • A 5-year view of Revenue shows it stood at $27000.0 in 2021, then plummeted by 70.37% to $8000.0 in 2022, then soared by 38487.5% to $3.1 million in 2023, then crashed by 100.45% to -$14000.0 in 2024, then soared by 1028.57% to $130000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Revenue are $130000.0 (Q2 2025), -$14000.0 (Q4 2024), and $14000.0 (Q3 2024).